4300 EL CAMINO REAL, SUITE 210, LOS ALTOS, CA
Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
Other Events
Announces Second Quarter 2025 Financial Results and Provides Business Update
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Announces Reverse Stock Split
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership